Lavipharm Labs
Lavipharm Labs is a Greek pharmaceutical company listed on the Athens Stock Exchange that develops and distributes outpatient specialty medicines, anchored by the Durogesic transdermal fentanyl patch licensed from Janssen/Johnson & Johnson, serving prescribers and outpatients in Greece and select international markets.
- Company typePublic
- Founded1911
- HeadquartersAthens, Greece
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Lavipharm Labs does
Lavipharm Labs is a Greek pharmaceutical company (legal entity Lavipharm SA) listed on the Athens Stock Exchange under ticker LAVI and headquartered in Athens, Greece. Founded in 1911, the company operates in the outpatient pharmaceutical segment with a stated focus on topical and transdermal drug delivery solutions, targeting healthcare providers and outpatients requiring pain management therapies.
The company's core product is Durogesic, a transdermal fentanyl patch for pain management, distributed and sold internationally under a licensing agreement with Janssen/Johnson & Johnson. This Durogesic agreement is positioned as the central lever of Lavipharm's international growth strategy, while product acquisitions and geographic diversification are projected as additional growth drivers. Beyond Durogesic, the portfolio approach emphasizes specialty outpatient pharmaceuticals; historical inorganic moves include the October 2000 acquisition of Separex for an undisclosed amount.
Lavipharm generates revenue primarily through pharmaceutical product sales spanning its domestic Greek market and international markets reached via the Durogesic agreement. In 2025 the company reported €70 million in consolidated sales (up 14.8% YoY), adjusted EBITDA of €15.4 million (up 49%), and net profits of €5.99 million. Outpatient market share rose from 0.7% in 2021 to 1.2% in 2025, signaling sustained share gain against a small base. Distribution is conducted through pharmacy networks and healthcare providers, with the company pursuing an enterprise field sales go-to-market focused on international market entry.
Lavipharm Labs firmographics
Firmographics- Name
- Lavipharm Labs
- Legal name
- Lavipharm SA
- Website
- https://lavipharm.gr
- Company type
- Public
- Founded year
- 1911
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Lavipharm Labs is a Greek pharmaceutical company listed on the Athens Stock Exchange that develops and distributes outpatient specialty medicines, anchored by the Durogesic transdermal fentanyl patch licensed from Janssen/Johnson & Johnson, serving prescribers and outpatients in Greece and select international markets.
- Ownership category
- akta.pro rank
Lavipharm Labs industry classification
Industry- Product category
- Pharmaceuticals
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834), Wholesale-Drugs, Proprietaries & Druggists' Sundries (5122)
- akta.pro primary industry
- Primary Care & General Medicine Pharmaceuticals (HLAIAAAA)
Keywords
Where Lavipharm Labs is headquartered
LocationHeadquarters
- HQ city
- Athens
- HQ country
- Greece
- HQ region
- Europe
Markets served
Lavipharm Labs business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Supply Chain, Operations, Personnel, Marketing or Sales, Technology or R&D
Revenue model
- Pharmaceutical Product Sales: Lavipharm generates revenue through the sale of pharmaceutical products including Durogesic (fentanyl patch). The company reported consolidated sales of 70 million euros in 2025, representing 14.8% growth year-over-year. Revenue is derived from both domestic Greek market and international expansion into new markets.
Go-to-market motion1 record
Lavipharm Labs product offering
Product offeringCore offering
Lavipharm Labs is a Greek pharmaceutical company that develops, distributes, and sells pharmaceutical products with a focus on topical and transdermal drug delivery solutions for the outpatient segment. Its portfolio is anchored by Durogesic (transdermal fentanyl patches), distributed internationally under a licensing agreement, and the company pursues growth through product acquisitions and geographic diversification.
Product overview
Lavipharm Labs is a Greek pharmaceutical company operating in the outpatient segment with a focus on topical and transdermal drug delivery solutions. The company operates with a portfolio strategy centered on Durogesic (transdermal fentanyl patches) as a key revenue driver, complemented by product acquisitions and geographic diversification efforts. The company increased its outpatient market share from 0.7% in 2021 to 1.2% in 2025, and projects future growth from new product acquisitions and international market expansion.
Differentiator
Problem solved
Functional benefit
Products and services
- Durogesic
Quantifiable outcome
- Market share increased from 0.7% to 1.2% in outpatient market (2021-2025)
- +2 more outcomes
Companies that use Lavipharm Labs
Customer profileSegments1 record
Ideal customer profiles1 record
Lavipharm Labs technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Lavipharm Labs partnerships and signals
Strategic signalScale indicators5 records
Recent moves4 records
Expansion highlights3 records
Lavipharm Labs competitors and assessment
Company assessmentDirect peers
- ELPEN Pharmaceutical: Greek pharmaceutical company with a comparable branded generics/specialty portfolio and outpatient market presence in Greece, making it a direct domestic peer for Lavipharm.
- Demo Pharmaceuticals: Athens-based pharmaceutical manufacturer with overlapping branded and specialty product offerings, serving similar outpatient channels and competing for the same Greek market share.
- Vianex: Established Greek pharmaceutical firm operating across branded and specialty therapeutics, comparable in scale and channel mix to Lavipharm in the domestic outpatient segment.
- Specifar Pharmaceuticals: Greek-focused pharmaceutical company with a similar generics and specialty portfolio, competing in the same outpatient channels and therapeutic categories as Lavipharm.
Broad incumbents
- Mundipharma: Global specialty pharmaceutical company with a strong focus on pain management, making it a comparable incumbent in the same therapeutic category where Lavipharm's Durogesic operates.
- Grünenthal: European pain-specialist pharmaceutical company with branded therapies and licensing/in-licensing models analogous to Lavipharm's Durogesic arrangement with J&J.
- Teva Pharmaceutical Industries: Large specialty/generics pharmaceutical company with European distribution scale and outpatient product breadth, comparable to Lavipharm as a broad pharma competitor in overlapping therapeutic categories.
- Viatris: Global pharmaceutical company with a large specialty and generics portfolio including pain therapies, representing a broad incumbent competing for the same outpatient prescription volumes Lavipharm targets.
- Stada Arzneimittel: European-focused specialty and generics pharmaceutical company with comparable mid-size scale and a similar strategy of branded/specialty product acquisitions in regional markets.
- Almirall: European specialty pharmaceutical company focused on dermatology and pain, comparable to Lavipharm as a mid-size European pharma with branded specialty products and international ambitions.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks6 records
Key highlights5 records
Customer concentration
Lavipharm Labs social profiles
Digital presenceLavipharm Labs financial estimates
Financial estimateRevenue estimate
Valuation estimate
Lavipharm Labs leadership team
Management profileNumber of profiles
Profiles1 record
Lavipharm Labs funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Lavipharm Labs M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Lavipharm Labs
What does Lavipharm Labs do?
Lavipharm Labs is a Greek pharmaceutical company that develops, distributes, and sells pharmaceutical products with a focus on topical and transdermal drug delivery solutions for the outpatient segment. Its portfolio is anchored by Durogesic (transdermal fentanyl patches), distributed internationally under a licensing agreement, and the company pursues growth through product acquisitions and geographic diversification.
Is Lavipharm Labs a public or private company?
Lavipharm Labs is a public company. It is classified as public and is currently operating.
When was Lavipharm Labs founded?
Lavipharm Labs was founded in 1911. It employs 11 to 50 people.
Where is Lavipharm Labs based?
Lavipharm Labs is headquartered in Athens, Greece, in the Europe region.
How does Lavipharm Labs make money?
One revenue line is on record: pharmaceutical Product Sales.
Who are Lavipharm Labs's main competitors?
Direct peers on record are ELPEN Pharmaceutical, Demo Pharmaceuticals, Vianex and Specifar Pharmaceuticals. Broad incumbents are Mundipharma, Grünenthal, Teva Pharmaceutical Industries, Viatris, Stada Arzneimittel and Almirall.
Does Lavipharm Labs have an API?
No public API is recorded for Lavipharm Labs.
What industry is Lavipharm Labs in?
Lavipharm Labs's product category is Pharmaceuticals. Its primary akta.pro industry code is HLAIAAAA, Primary Care & General Medicine Pharmaceuticals. Its NAICS code is 325412 and its SIC code is 2834.